DermatologyNews.net

Dermatology Xagena

Xagena Mappa
Medical Meeting
Neurobase.it
Onco News

Keytruda ( Pembrolizumab ) is a humanized monoclonal antibody that works by increasing the ability of the body’s immune system to help detect and fight tumor cells. Pembrolizumab blocks the interactio ...


Few therapeutic alternatives currently exist in the treatment of papulopustular rosacea. The aim of a study was to demonstrate superiority of once-daily Ivermectin ( Efacti; Soolantra ) 1% cream on ...


Chemotherapy-induced alopecia ( CIA ) is a highly distressing event for cancer patients. A study aimed to assess the efficacy of various interventions in the prevention of chemotherapy-induced alopeci ...


Side effects associated with oral Finasteride ( 1 mg/d ) and topical 5% Minoxidil have been previously described. The long-term adverse effects and causes of long-term therapy withdrawal in patien ...


There is strong evidence for an autoimmune etiology of alopecia areata. Interleukin-17A ( IL-17A ) is a Th17 proinflammatory cytokine that has been linked to the pathogeneses of diverse autoimmune and ...


New data demonstrating that Cosentyx ( Secukinumab ) provides high levels of skin clearance and sustained efficacy in patients with moderate-to-severe plaque psoriasis while maintaining a favorable sa ...


The results of a phase I study in advanced melanoma suggested complementary clinical activity with Nivolumab ( Opdivo ), a PD-1 checkpoint inhibitor, plus Ipilimumab ( Yervoy ), a CTLA-4 checkpoint in ...


Keytruda ( Pembrolizumab ) is indicated in the United States at a dose of 2 mg/kg administered as an intravenous infusion over 30 minutes every three weeks for the treatment of patients with ...


Rosmarinus officinalis L. is a medicinal plant with diverse activities including enhancement microcapillary perfusion. A study has investigated the clinical efficacy of rosemary oil in the treatment ...


Rosmarinus officinalis L. is a medicinal plant with diverse activities including enhancement microcapillary perfusion. A study aimed to investigate the clinical efficacy of rosemary oil in the tre ...


Phase II trial results from investigational compound BI 655066 were presented at 73rd Annual Meeting of the American Academy of Dermatology. Nearly double the percentage of patients with moderate-to ...


In clinical practice, patients with psoriasis may require intermittent therapy as part of their long-term treatment programme. Those achieving Physician's Global Assessment ( PGA ) of less than or equ ...


Finasteride ( Propecia ) at a dose of 1 mg/d has been reported to show no significant improvement in 30–50% of patients with androgenetic alopecia. Dutasteride ( Avodart ), a dual inhibitor of both ...


The incidence of non-infectious uveitis on a background of psoriasis is estimated to be 7-20%. The use of tumor necrosis factor-alpha ( TNF-alpha ) inhibitors as a treatment for refractory uveitis is ...


The phase IIIb CLEAR study for Secukinumab ( Cosentyx ) has demonstrated superiority to Ustekinumab ( Stelara ) and met its primary endpoint of achieving PASI 90, which represents clear or almost clea ...